APO Research, Inc.

Find your market.

Compare the product scope, applications and research editions relevant to your next decision.

Our research approach
Browse the complete product directory →

9,053 topics, 45,265 reports

Clear all filters

Pharma & Healthcare

Nanoemulsions

Emulsion is the process of suspension of small globules of one liquid into other such that the fluids are immiscible with each other. Nanoemulsions are the group of dispersed nano-particles of oil in water having extremely minute size of 100-600 nm. The nanoemulsions are prepared using various emulsification techniques such as microfluidization, high-pressure homogenization and sonication (use of ultrasound energy).

Types
Steroids · Anesthetics · NSAIDs
Applications
Pharmaceutical Industrial · Cosmetic Industrial · Food Industrial

5 editions21 December 2025

View 5 research editions
$3,450Single user · USD · Industry Growth & TrendsExplore product: NanoemulsionsCompare research options for Nanoemulsions

Pharma & Healthcare

Interactive AI Service

Types
Intelligent Car · Intelligent Customer Service · Smart Home
Applications
Urban Management and Administration · Finance · Automobile and Transportation

5 editions29 December 2025

View 5 research editions

Pharma & Healthcare

mRNA Vaccines & Therapeutics

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has…

Types
Infectious Disease Vaccines · Cancer Vaccines
Applications
Infectious Disease · Cancer

5 editions28 December 2025

View 5 research editions

Pharma & Healthcare

Rivaroxaban

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so…

Types
2.5 mg · 10 mg · 15 mg
Applications
Acute Coronary Syndrome (ACS) · Venous Thromboembolism (VTE)

5 editions1 January 2026

View 5 research editions

Pharma & Healthcare

TB Vaccines

Types
Immunotherapeutic Vaccines · Booster Vaccines · Others
Applications
Private Clinics · Research Institutes · Hospitals

5 editions19 December 2025

View 5 research editions
$3,450Single user · USD · Industry Growth & TrendsExplore product: TB VaccinesCompare research options for TB Vaccines
APO Research, Inc.